REVOLUTION MEDICINES INC (1RVMD.MI) Stock Price, Forecast & Analysis
BIT:1RVMD • US76155X1000
1RVMD.MI Key Statistics, Chart & Performance
The current stock price of 1RVMD.MI is 83 EUR.
1RVMD.MI Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to 1RVMD.MI.
1RVMD.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to 1RVMD.MI. While 1RVMD.MI seems to be doing ok healthwise, there are quite some concerns on its profitability.
1RVMD.MI Financial Highlights
Over the last trailing twelve months 1RVMD.MI reported a non-GAAP Earnings per Share(EPS) of -4.38. The EPS decreased by -44.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.65% | ||
| ROE | -37.58% | ||
| Debt/Equity | 0.16 |
1RVMD.MI Forecast & Estimates
27 analysts have analysed 1RVMD.MI and the average price target is 100.64 EUR. This implies a price increase of 21.25% is expected in the next year compared to the current price of 83.
For the next year, analysts expect an EPS growth of -59.94% and a revenue growth 1279.08% for 1RVMD.MI
1RVMD.MI Ownership
1RVMD.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 26.84 | 42.155B | ||
| ARGX | ARGENX SE | 25.91 | 40.348B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.218B | ||
| ABVX | ABIVAX SA | N/A | 8.129B | ||
| 2X1 | ABIVAX SA | N/A | 8.129B | ||
| GXE | GALAPAGOS NV | N/A | 1.914B | ||
| GLPG | GALAPAGOS NV | N/A | 1.866B | ||
| 6IV | INVENTIVA SA | N/A | 1.174B | ||
| IVA | INVENTIVA SA | N/A | 1.145B | ||
| NANO | NANOBIOTIX | N/A | 1.11B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1RVMD.MI
Company Profile
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. The company is headquartered in Redwood City, California and currently employs 809 full-time employees. The company went IPO on 2020-02-13. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
Company Info
REVOLUTION MEDICINES INC
700 Saginaw Dr
Redwood City CALIFORNIA US
Employees: 809
Phone: 13026365400
REVOLUTION MEDICINES INC / 1RVMD.MI FAQ
What does REVOLUTION MEDICINES INC do?
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. The company is headquartered in Redwood City, California and currently employs 809 full-time employees. The company went IPO on 2020-02-13. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
What is the current price of 1RVMD stock?
The current stock price of 1RVMD.MI is 83 EUR. The price decreased by -17% in the last trading session.
What is the dividend status of REVOLUTION MEDICINES INC?
1RVMD.MI does not pay a dividend.
What is the ChartMill rating of REVOLUTION MEDICINES INC stock?
1RVMD.MI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What sector and industry does REVOLUTION MEDICINES INC belong to?
REVOLUTION MEDICINES INC (1RVMD.MI) operates in the Health Care sector and the Biotechnology industry.